| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(1 year, 8 months ago) | |
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(3 months from now) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(5 months from now) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(5 months from now) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(7 months from now) | |
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(1 year, 10 months from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(4 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(5 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(6 years from now) | |
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(9 years from now) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(10 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(9 years from now) | |
Givlaari is owned by Alnylam Pharms Inc.
Givlaari contains Givosiran Sodium.
Givlaari has a total of 14 drug patents out of which 1 drug patent has expired.
Expired drug patents of Givlaari are:
- US8546143
Givlaari was authorised for market use on 20 November, 2019.
Givlaari is available in solution;subcutaneous dosage forms.
Givlaari can be used as treatment of acute hepatic porphyria.
Drug patent challenges can be filed against Givlaari from 2023-11-21.
The generics of Givlaari are possible to be released after 03 October, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 2023-11-21
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
GIVLAARI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic